BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOGEN INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$233.48+0.83 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $34.72B
- P/E (TTM)
- 41.3
- Dividend yield
- –
BIOGEN INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $1.92B | $1.75B | $1.67B | $1.85B | $1.88B | $1.73B | $1.83B | $1.77B | $1.90B | $1.71B | $1.83B | $1.81B | 70.0% | +2.0% |
| MS Product Revenues | $963.30M | $957.50M | $917.20M | $1.06B | $1.11B | $953.00M | $1.07B | $1.05B | $1.15B | $1.08B | $1.17B | $1.16B | 35.2% | -13.0% |
| Rare Disease Product Revenue | $601.70M | $557.20M | $514.60M | $533.30M | $543.00M | $563.30M | $535.30M | $494.80M | $534.10M | $423.90M | $471.80M | $449.90M | 22.0% | +10.8% |
| Revenue from anti-CD20 therapeutic programs | $513.50M | $419.10M | – | $493.90M | $467.30M | $378.20M | – | $446.20M | $444.50M | $394.00M | – | $420.90M | 18.8% | +9.9% |
| TYSABRI | $450.80M | $441.50M | $397.50M | $431.80M | $454.60M | $381.50M | $415.40M | $406.10M | $462.20M | $431.30M | $464.70M | $456.30M | 16.5% | -0.8% |
| SPINRAZA | $401.90M | $374.00M | $356.20M | $374.00M | $392.70M | $423.90M | $421.40M | $381.40M | $429.10M | $341.30M | $412.60M | $448.20M | 14.7% | +2.3% |
| Royalty Attributed To OCREVUS | $381.40M | $317.20M | $385.90M | $386.40M | $353.80M | $288.80M | $353.70M | $346.80M | $336.30M | $302.70M | $338.00M | $319.10M | 13.9% | +7.8% |
| Fumarate | $287.40M | $288.50M | $292.90M | $382.80M | $405.90M | $344.90M | $404.40M | $390.90M | $418.00M | $381.80M | $400.70M | $405.00M | 10.5% | -29.2% |
| Contract manufacturing, royalty and other revenue | $242.40M | $246.90M | – | $151.20M | $244.60M | $293.30M | – | $231.60M | $109.00M | $181.80M | – | $304.20M | 8.9% | -0.9% |
| Contract manufacturing revenue | $232.40M | $237.20M | $30.60M | $141.50M | $225.00M | $282.30M | $118.00M | $221.90M | $100.00M | $152.20M | $105.30M | $252.90M | 8.5% | +3.3% |
| Interferon | $225.10M | $227.50M | $225.70M | $246.90M | $246.70M | $226.30M | $236.00M | $237.50M | $250.90M | $243.60M | $280.00M | $277.70M | 8.2% | -8.8% |
| VUMERITY | $196.50M | $179.00M | $181.10M | $214.60M | $212.30M | $138.80M | $176.60M | $158.10M | $165.80M | $127.50M | $156.40M | $165.50M | 7.2% | -7.4% |
| AVONEX | $170.00M | $163.20M | $162.50M | $188.50M | $177.70M | $166.80M | $170.00M | $176.20M | $182.80M | $178.50M | $206.10M | $212.20M | 6.2% | -4.3% |
| SKYCLARYS | $167.90M | $150.70M | $133.40M | $132.90M | $130.30M | $123.90M | $102.20M | $102.30M | $100.00M | $78.00M | $55.90M | $0 | 6.1% | +28.9% |
| Biosimilars | $152.80M | $182.20M | $169.80M | $196.80M | $181.70M | $180.80M | $201.50M | $196.60M | $198.10M | $196.90M | $188.20M | $194.30M | 5.6% | -15.9% |
| Specialized Immunology | $127.80M | – | – | – | $0 | – | – | – | – | – | – | – | 4.7% | – |
| BENEPALI | $106.80M | $122.10M | $107.90M | $121.90M | $112.10M | $111.30M | $125.00M | $118.10M | $117.30M | $118.70M | $107.80M | $112.80M | 3.9% | -4.7% |
| SYFOVRE | $97.40M | – | – | – | $0 | – | – | – | – | – | – | – | 3.6% | – |
| TECFIDERA | $90.90M | $109.50M | $111.80M | $168.20M | $193.60M | $206.10M | $227.80M | $232.80M | $252.20M | $254.30M | $244.30M | $239.50M | 3.3% | -53.0% |
| Other | $70.80M | $55.40M | – | $55.30M | $46.80M | $29.40M | – | $24.10M | $17.60M | $15.20M | – | $2.00M | 2.6% | +51.3% |
| ZURZUVAE | $70.80M | $55.40M | $65.70M | $55.30M | $46.40M | $27.70M | $22.90M | $22.00M | $14.90M | $12.40M | $1.60M | $0 | 2.6% | +52.6% |
| Alzheimer's collaboration revenue | $63.70M | $59.50M | – | $42.70M | $54.90M | $33.00M | – | $18.60M | $11.80M | $2.80M | – | – | 2.3% | +16.0% |
| Alzheimer's Collaboration | $63.70M | $59.50M | $47.10M | $42.70M | $54.90M | $33.00M | $26.70M | $18.60M | $11.80M | $2.80M | – | – | 2.3% | +16.0% |
| PLEGRIDY | $55.10M | $64.30M | $63.20M | $58.40M | $69.00M | $59.50M | $66.00M | $61.30M | $68.10M | $65.10M | $73.90M | $65.50M | 2.0% | -20.1% |
| IMRALDI | $37.80M | $49.60M | $43.50M | $52.60M | $46.70M | $47.40M | $51.00M | $54.10M | $53.20M | $54.80M | $54.50M | $54.40M | 1.4% | -19.1% |
| QALSODY | $31.90M | $32.50M | $25.00M | $26.40M | $20.00M | $15.50M | $11.70M | $11.10M | $5.00M | $4.60M | $3.30M | $1.70M | 1.2% | +59.5% |
| EMPAVELI | $30.40M | – | – | – | $0 | – | – | – | – | – | – | – | 1.1% | – |
| Royalty and other revenue | $10.00M | $9.70M | $13.20M | $9.70M | $19.60M | $11.00M | $12.20M | $9.70M | $9.00M | $29.60M | $12.80M | $51.30M | 0.4% | -49.0% |
| FLIXABI | $8.10M | $10.50M | $9.90M | $15.30M | $14.30M | $13.10M | $16.10M | $16.20M | $13.10M | $17.80M | $16.70M | $20.20M | 0.3% | -43.4% |
| BYOOVIZ | $100.00K | $0 | $7.90M | $7.00M | $8.60M | $8.90M | $9.30M | $8.00M | $13.70M | $5.60M | $9.20M | $6.90M | 0.0% | -98.8% |
| FAMPYRA | $0 | $0 | $1.10M | $0 | $0 | $300.00K | $14.40M | $19.40M | $18.70M | $19.20M | $23.00M | $20.00M | 0.0% | – |
| FUMADERM And ADUHELM | $0 | $0 | $0 | $0 | $400.00K | $1.70M | $2.70M | $2.10M | $2.70M | $2.80M | $2.40M | $2.00M | 0.0% | -100.0% |
| TOFIDENCE | $0 | $0 | $600.00K | $0 | $0 | $100.00K | $100.00K | $200.00K | $800.00K | $0 | $0 | $0 | 0.0% | – |
| Spinal Muscular Atrophy | – | – | – | – | – | – | – | – | – | – | – | $448.20M | – | – |
By region
From the segment and revenue-disaggregation notes of Biogen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.